Panbela Therapeutics Inc. (NASDAQ:PBLA) shares traded -13.60% lower at $0.09 on Wall Street last session.
In accordance with the data, 1 analysts cover Panbela Therapeutics Inc. (NASDAQ:PBLA). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $6.00, we find $6.00. Given the previous closing price of $0.11, this indicates a potential upside of 5354.55 percent. PBLA stock price is now -48.84% away from the 50-day moving average and -91.42% away from the 200-day moving average. The market capitalization of the company currently stands at $3.18M.
It has been rated a hold by 1 analysts and a buy by 0. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
A total of 2.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PBLA stock. A new stake in Panbela Therapeutics Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $200,000. VANGUARD GROUP INC invested $20,000 in shares of PBLA during the first quarter. In the first quarter, CLEAR STREET LLC acquired a new stake in Panbela Therapeutics Inc. valued at approximately $10,000. VIRTU FINANCIAL LLC acquired a new stake in PBLA for approximately $7,000. OXFORD FINANCIAL GROUP LTD purchased a new stake in PBLA valued at around $2,000 in the second quarter. In total, there are 13 active investors with 9.40% ownership of the company’s stock.
Panbela Therapeutics Inc. (NASDAQ: PBLA) opened at $0.1090 on Tuesday. During the past 12 months, Panbela Therapeutics Inc. has had a low of $0.10 and a high of $2.40. The fifty day moving average price for PBLA is $0.1801 and a two-hundred day moving average price translates $1.0729 for the stock.
The latest earnings results from Panbela Therapeutics Inc. (NASDAQ: PBLA) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$1.51, missing analysts’ expectations of -$0.25 by -1.26. This compares to -$0.16 EPS in the same period last year. The company reported revenue of $3.62 million for the quarter, compared to $2.21 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 63.94 percent.
Panbela Therapeutics Inc.(PBLA) Company Profile
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.